• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
  

PubMed=2785141; DOI=10.4049/jimmunol.142.9.3329
Darrow T.L., Slingluff C.L. Jr., Seigler H.F.
The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
J. Immunol. 142:3329-3335(1989)

PubMed=2404572
Crowley N.J., Slingluff C.L. Jr., Darrow T.L., Seigler H.F.
Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
Cancer Res. 50:492-498(1990)

PubMed=7703289; DOI=10.1089/hum.1995.6.1-87
Fenton R.T., Sznol M., Luster D.G., Taub D.D., Longo D.L.
A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401.
Hum. Gene Ther. 6:87-106(1995)

PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162
Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D., Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J., Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F., Darrow T.L., Engelhard V.H.
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Cancer Immunol. Immunother. 48:661-672(2000)

PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209
Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res. 64:1157-1163(2004)

PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461
Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J., Brautigan D.L., Slingluff C.L. Jr.
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Melanoma Res. 21:274-284(2011)

PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389
Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd, Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.
Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma.
PLoS ONE 10:E0138210-E0138210(2015)

PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068
Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R., Petricoin E.F. 3rd, Gioeli D., Weber M.J.
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Oncotarget 7:2734-2753(2016)